NASDAQ:GLMD • IL0011313900
The current stock price of GLMD is 0.609 USD. In the past month the price decreased by -22.15%. In the past year, price decreased by -75.54%.
ChartMill assigns a fundamental rating of 2 / 10 to GLMD. GLMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GLMD reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 85.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.31% | ||
| ROE | -45.52% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
GALMED PHARMACEUTICALS LTD
16 Tiomkin Street
TEL AVIV-YAFO 6578317 IL
CEO: Allen Baharaff
Employees: 3
Phone: 97236938448
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
The current stock price of GLMD is 0.609 USD. The price decreased by -8.71% in the last trading session.
GLMD does not pay a dividend.
GLMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
GALMED PHARMACEUTICALS LTD (GLMD) operates in the Health Care sector and the Biotechnology industry.
GALMED PHARMACEUTICALS LTD (GLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.6).
GALMED PHARMACEUTICALS LTD (GLMD) has a market capitalization of 4.35M USD. This makes GLMD a Nano Cap stock.